Gilteritinib Improves Survival in Patients with Relapsed/Refractory FLT3+ AML

Treatment with gilteritinib improved survival and increased remission rates, compared with salvage chemotherapy, among patients with relapsed or refractory FLT3-mutated acute myeloid leukemia.

Source: CancerNetwork - November 1, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news